Who Generates Higher Gross Profit? Gilead Sciences, Inc. or Grifols, S.A.

Gilead vs. Grifols: A Decade of Profit Trends

__timestamp	Gilead Sciences, Inc.	Grifols, S.A.
Wednesday, January 1, 2014	21102000000	1699214000
Thursday, January 1, 2015	28633000000	1930998000
Friday, January 1, 2016	26129000000	1912291000
Sunday, January 1, 2017	21736000000	2152011000
Monday, January 1, 2018	17274000000	2049560000
Tuesday, January 1, 2019	17774000000	2341232000
Wednesday, January 1, 2020	20117000000	2255165000
Friday, January 1, 2021	20704000000	1962596000
Saturday, January 1, 2022	21624000000	2231530000
Sunday, January 1, 2023	20618000000	2322701000
Monday, January 1, 2024	78200000

Infusing magic into the data realm

Gilead Sciences vs. Grifols: A Decade of Gross Profit

In the competitive landscape of the pharmaceutical industry, Gilead Sciences, Inc. and Grifols, S.A. have been key players. Over the past decade, Gilead Sciences has consistently outperformed Grifols in terms of gross profit. From 2014 to 2023, Gilead's gross profit peaked in 2015, reaching nearly 30% higher than its average over the period. In contrast, Grifols showed a steady increase, with its highest gross profit in 2019, marking a 38% rise from its 2014 figures.

While Gilead's profits have fluctuated, Grifols has demonstrated a more stable growth trajectory. This trend highlights Gilead's dominance in the market, yet also underscores Grifols' resilience and potential for future growth. As the pharmaceutical industry evolves, these financial insights provide a glimpse into the strategic maneuvers of these two giants.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025